382606-12-4

Basic information

• Product Name: (4-Nitro-phenyl)-acetic acid (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((2S,3R,4S,6R)-3-acetoxy-4-dimethylamino-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-12,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-4-yl ester
• Synonyms: (4-Nitro-phenyl)-acetic acid (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((2S,3R,4S,6R)-3-acetoxy-4-dimethylamino-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-12,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-4-yl ester
• CAS NO: 382606-12-4
• Molecular Weight: 794.937
• Mol File: 382606-12-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (4-Nitro-phenyl)-acetic acid (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((2S,3R,4S,6R)-3-acetoxy-4-dimethylamino-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-12,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-4-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Nitro-phenyl)-acetic acid (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((2S,3R,4S,6R)-3-acetoxy-4-dimethylamino-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-12,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-4-yl ester(382606-12-4)
• EPA Substance Registry System: (4-Nitro-phenyl)-acetic acid (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((2S,3R,4S,6R)-3-acetoxy-4-dimethylamino-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-12,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-4-yl ester(382606-12-4)

Safety Data

• Hazardous Substances Data: 382606-12-4(Hazardous Substances Data)

Upstream product

• 118058-74-5 3-O-descladinosylclarithromycin 
• 81103-11-9 clarithromycin 
• 104-03-0 4-nitrobenzeneacetic acid 
• 143353-81-5 3-Ode-[(2,6-dideoxy-3-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-6-O-methylerythromycin 2￠-acetate 

Relevant articles and documents

Rational prioritization strategy allows the design of macrolide derivatives that overcome antibiotic resistance

Antibiotic resistance is a major threat to global health; this problem can be addressed by the development of new antibacterial agents to keep pace with the evolutionary adaptation of pathogens. Computational approaches are essential tools to this end since their application enables fast and early strategical decisions in the drug development process. We present a rational design approach, inwhich acylide antibiotics were screened based on computational predictions of solubility, membrane permeability, and binding affinity toward the ribosome. To assess our design strategy, we tested all candidates for in vitro inhibitory activity and then evaluated them in vivo with several antibioticresistant strains to determine minimal inhibitory concentrations. The predicted best candidate is synthetically more accessible, exhibits higher solubility and binding affinity to the ribosome, and is up to 56 times more active against resistant pathogens than telithromycin. Notably, the best compounds designed by us show activity, especially when combined with the membraneweakening drug colistin, against Acinetobacter baumanii, Pseudomonas aeruginosa, and Escherichia coli, which are the three most critical targets from the priority list of pathogens of the World Health Organization.

Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): A novel class of macrolide antibiotics

Introduction of an acyl group to the 3-O-position of erythromycin A derivatives instead of L-cladinose led to a novel class of macrolide antibiotics that we named "acylides". The 3-O-nitrophenylacetyl derivative TEA0777 showed significantly potent activit